NcXHF

WEINSTOCK AND MCDERMOTT
PD-1 in the treatment of solid tumors. https://www.clinicaltrials.gov/
ct2/show/NCT01968109. Accessed January 28, 2015.
61. NCT01975831. A phase 1 study to evaluate medi4736 in combination with
tremelimumab. https://www.clinicaltrials.gov/ct2/show/NCT01975831. Accessed
January 28, 2015.
62. NCT02118337. A phase 1, open-label study to evaluate the safety and
tolerability of MEDI0680 (AMP-514) in combination with MEDI4736
in subjects with advanced malignancies. https://www.clinicaltrials.
gov/ct2/show/NCT02118337. Accessed January 28, 2015.
63. NCT02014636. Safety and effıcacy study of pazopanib and MK 3475 in
advanced renal cell carcinoma (RCC). https://www.clinicaltrials.gov/
ct2/show/NCT02014636. Accessed January 28, 2015.
64. NCT02133742. A dose fınding study to evaluate safety, drug interaction,
tumor markers of axitinib in combination with MK-3475 in adult
patients with previously untreated advanced renal cell cancer. https://
www.clinicaltrials.gov/ct2/show/NCT02133742. Accessed January 28,
2015.
65. NCT02231749. Nivolumab combined with ipilimumab versus
sunitinib in previously untreated advanced or metastatic renal cell
carcinoma (CheckMate 214). https://www.clinicaltrials.gov/ct2/show/
NCT02231749. Accessed January 28, 2015.
66. Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer
with interleukin-2 following nivolumab (anti-PD-1) treatment. J Immunother.
2014;37:187-191.
67. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell
genes. Proc Natl Acad SciUSA.1989;86:1963-1967.
68. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol.
1998;10:481-489.
69. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bone fıde
CD8 T cell survival signal. J Immunol. 1999;162:5037-5040.
70. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory
to previously activated splenic T cells and inhibit activationinduced
cell death. J Immunol. 1997;158:2600-2609.
71. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory
signals preferentially induced CD8 T cell proliferation and lead to
amplifıcation in vivo of cytotoxic T cell responses. J Exp Med. 1997;
186:47-55.
72. Westwood JA, Darcy PK, Guru PM, et al. Three agonist antibodies in
combination with high-dose IL-2 eradicate orthotopic kidney cancer
in mice. J Transl Med. 2010;8:42.
73. Jua SA, Cheon SH, Park SM, et al. Eradication of established renal cell
carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal
antibody in mice. Int J Cancer. 2008;122:2784-2790.
74. NCT02179918. A study of 4-1BB agonist PF-05082566 plus PD-1 inhibitor
MK-3475 in patients with solid tumors (B1641003/KEYNOTE-0036).
https://www.clinicaltrials.gov/ct2/show/NCT02179918. Accessed February
2, 2015.
75. Sondergaard H, Frederiksen KS, Thygesen P, et al. Interleukin-21 therapy
increases the density of tumor infıltrating CD8 T cells and inhibits
the growth of syngeneic tumors. Cancer Immunol Immunother.
2007;56:1417-1428.
76. Kumano M, Hara I, Furukawa J, et al. Interleukin-21 activates cytotoxic
T lymphocytes and natural killer cells to generate antitumor response
in mouse renal cell carcinoma. J Urol. 2007;178:1504-1509.
77. Thompson JA, Curti BD, Redman BG, et al. Phase I study of recombinant
interleukin-21 in patients with metastatic melanoma and renal
cell carcinoma. J Clin Oncol. 2008;26:2034-2039.
78. Grunwald V, Desar IM, Haanen J, et al. A phase I study of recombinant
human interleukin-21 (rIL-21) in combination with sunitinib in patients
with metastatic renal cell carcinoma (RCC). Acta Oncol. 2011;
50:121-126.
79. Bhatia S, Curti B, Ernstoff, et al. Recombinant interleukin-21 plus
sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother
Cancer. 2014;2:2.
80. Gershon RK, Kondo K. Cell interactions in the induction of tolerance:
the role of thymic lymphocytes. Immunology. 1970;18:723-737.
81. Janeway CA, Sharrow SO, Simpson E. T cell populations with different
functions. Nature. 1975;253-254.
82. Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the
development and function of human CD25CD4 regulatory T cells.
Int Immunol. 2005;16:1643-1656.
83. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profıle
and specifıc expression of chemokine receptors CCR4 and CCD8
by CD4()CD25() regulatory T cells. J Exp Med. 2001;194:847-853.
84. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of
CCD4 in adult T-cell leukemia and human T-cell leukemia virus type
1-transformed T cells. Blood. 2002;99:1505-1511.
85. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy
of cancer. Cancer Sci. 2006;97:1139-1146.
86. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively
depletes effector-type FoxP3CD4 regulatory T cells, evoking antitumor
immune responses in humans. Proc Natl Acad SciUSA.2013;
110:17945-17950.
87. Cozar JM, Canton J, Tallada M, et al. Analysis of NK cells and chemokine
receptors in tumor infıltrating CD4 T lymphocytes in human renal
carcinomas. Cancer Immunol Immunother. 2005;54:858-866.
88. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated
antitumor activity in cancer patients after depletion of regulatory T
cells. J Clin Invest. 2005;115:3623-3633.
89. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab
to enhance immune responses to tumor antigen vaccination by
targeting T regulatory cells. Ann N Y Acad Sci. 2009;1174:99-106.
90. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
91. Aubert S, Fauquette V, Hemon B, et al. MUC1, a new hypoxia inducible
factor target gene, is an actor in clear renal cell carcinoma tumor
progression. Cancer Res. 2009;69:5707-5715.
92. Griffıths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoetal
antigen in renal cell carcinoma: a potential target for T-cellbased
immunotherapy. Br J Cancer. 2005;93:670-677.
93. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a
modifıed vaccinia virus (MVA) expressing human MUC1 as antigenspecifıc
immunotherapy in patients with MUC1-positive advanced
cancer. J Gene Med. 2003;5:690-699.
94. Oudard S, Rixe O, Beuselinck B, et al. A phase II study of the cancer
vaccine TG4010 alone and in combination with cytokines in patients
with metastatic renal clear-cell carcinoma: clinical and immunological
fındings. Cancer Immunol Immunother. 2011;60:261-271.
95. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal
cancer patients with MVA-5T4: a randomized, double-blind, placebocontrolled
phase III study. Clin Cancer Res. 2010;16:5539-5547.
96. Motzer RJ, Mazmudar M, Bacik J, et al. Survival and prognostic stratifıcation
of 670 patients with advanced renal cell carcinoma. J Clin Oncol.
1999;17:2530-2540.
97. Pal SK, Hu A, Figlin RA. A new age for vaccine therapy in renal cell
carcinoma. Cancer J. 2013;19:365-370.
98. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response
to cancer vaccine IMA901 after single-dose cyclophosphamide
associates with longer patient survival. Nat Med. 2012;18:1254-1261.
99. NCT01265901. IMA901 in patients receiving sunitinib for advanced/
metastatic renal cell carcinoma. https://clinicaltrials.gov/ct2/show/
NCT01265901. Accessed February 6, 2015.
100. Figlin RA, Nicolette CA, Amin A, et al. Monitoring T-cell responses in a
phase II study of AGS-003, an autologous dendritic cell-based therapy in
e296
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook